REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Lymphokine > Interferon > Beta Or Fibroblast Beta Or FibroblastBeta Or Fibroblast patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/12/07 - 20070160580 - Interferon gamma therapies for idiopathic pulmonary fibrosis The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-&ggr, to an individual with IPF. ... 05/17/07 - 20070110715 - Treatment of alzheimer's disease The present invention. The invention relates to the use of interferon-β (IFN-β) for treating and/or preventing Alzheimer's disease (AD), Creutzfeld-Jakob disease (CJD) or Gerstmann-Sträussler-Scheinker disease (GSSD). It further relates to the use of IFN-β in combination with an Alzheimer's disease treating agent for treating and/or preventing Alzheimer's disease. The use ... 05/10/07 - 20070104683 - Composition and methods for affecting metallocorrinoid uptake The present invention is directed to compositions and methods for affecting metallocorrinoid uptake. The compositions and methods of the present invention are particularly useful in enhancing the uptake or availability of biologically active metallocorrinoids (e.g. cobalamin and its analogs). The present invention is particularly useful in the treatment or prevention ... 05/10/07 - 20070104682 - Stabilized interferon liquid formulations Stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said formulation is a solution that comprises a buffer, a cyclodextrin, an isotonicity agent and an anti-oxidant are described here. Preferably the interferon is interferon beta-1a and the ... 05/03/07 - 20070098688 - Polymer conjugates of interferon beta-1a and uses An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as ... 04/26/07 - 20070092488 - Methods of treating idiopathic pulmonary fibrosis The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF. ... 04/26/07 - 20070092487 - Stabilized liquid protein formulations in pharmaceutical containers A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFLON and contains a HSA-free Interferon-β formulation having the following composition: 30 to 100 μg/ml of interferon-β, an isotonicity agent, 0.1 to ... 04/12/07 - 20070081976 - Bioconjugates comprising sulfated polysaccharides and their uses The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can be a heparin-binding polypeptide and/or a positively-charged polypeptide. Also, provided are delivery systems and ... 03/08/07 - 20070053877 - Methods of treating idiopathic pulmonary fibrosis The present application provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF, and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF. ... 02/08/07 - 20070031377 - Treatment of type 1 immune response-mediated inflammatory lung disease by modulation of ifn-gamma activity The present invention relates to preventing, or treating and/or reducing the severity or progression of Type 1 immune response-mediated inflammatory lung disease. More particularly, the present invention provides a method for preventing or treating chronic obstructive pulmonary disease (COPD), severe asthma, sarcoidosis, berylliosis or cystic fibrosis by neutralizing or reducing ... 01/25/07 - 20070020234 - Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor Hepatocyte growth factor/scatter factor (HGF/SF), acting through the Met receptor, plays an important role in most human solid tumors and inappropriate expression of this ligand-receptor pair is often associated with poor prognosis. The molecular basis for the malignant activity imparted by signaling of HGF/SF-Met in cancer cells has been attributed ... 12/14/06 - 20060280723 - Interferon for treating or preventing a coronaviral infection The present invention provides a composition and method for use in the prevention or treatment of a coronaviral infection and in particular, the human coronavirus infection termed severe acute respiratory syndrome (SARS) coronavirus (SARS-HCoV). A method of treating a coronaviral infection is provided through the administration of interferon, further the ... 11/09/06 - 20060251619 - Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides Provided are modified interferon-gamma (IFN-γ) polypeptides and methods of generating modified interferon-gamma polypeptides. Also provided are methods of treatment using modified interferon-gamma polypeptides. ... 11/02/06 - 20060246034 - Interferon-beta composite The present invention relates to a complex between interferon-β and polyethylene glycol, which has high biological activity, and to a method for producing the complex at high efficiency. Namely, the present invention relates to a method for producing an interferon-β complex comprising binding interferon-β to polyethylene glycol in the presence ... 10/12/06 - 20060228332 - Assembly and folding of fc-interferon-beta fusion proteins Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using ... 08/31/06 - 20060193828 - Expression enhancer for hm1.24 antigen An enhancer of expression, in the myeloma cell, of HM1.24 antigen, said enhancer comprising interferon-α or interferon-γ, or IRF-2 protein as an active ingredient. Interferon-α or interferon-γ is expected to enhance the expression of HM1.24 antigen by activating the promoter of a gene encoding HM1.24 antigen. ... 08/17/06 - 20060182716 - Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention further provides oral formulations of protease-resistant or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least ... 08/17/06 - 20060182715 - Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-ss The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics. ... 07/13/06 - 20060153803 - Inhibition of sars coronavirus infection with clinically approved antiviral drugs The invention relates to methods for treating or inhibiting SARS-CoV infection involving the administration of an interferon, particularly IFN α-n1, IFN α-n3, human leukocyte IFN α or IFN β-1b. ... 06/29/06 - 20060140907 - Central airway administration for systemic delivery of therapeutics The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of ... 06/08/06 - 20060120998 - Deamidated interferon-beta Interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-β, is deamidated exhibit a biological activity of native human interferon-β at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in ... 05/25/06 - 20060110358 - Combination therapy for treatment of fibrotic disorders The present invention provides methods of treating a fibrotic disorder. The methods generally involve administering an effective amount of IFN-γ and an effective amount of pirfenidone or a pirfenidone analog. ... 05/18/06 - 20060104947 - Remedy for pemphigoid An agent for treatment of pemphigoid is provided. For use as an agent for treatment of pemphigoid, IFN-γ is administered in a dose of 2,000,000 JRU once daily for 7 days by intravenous drip infusion. Depending on symptoms, side effects and age of a patient, the dose can be change, ... 05/11/06 - 20060099176 - Medicines including interferon and administering system thereof The present invention discloses medicines including interferon and administering systems thereof, which have characteristics of the preparation according to the number of interferon on the surface of the cell and/or 2-5AS activity induced in the cell. The administering system of the present invention includes the first step of detecting the ... 05/11/06 - 20060099175 - Full-length interferon gamma polypeptide variants The present invention relates to novel full-length interferon gamma (IFNG) polypeptide variants having interferon gamma activity. The full-length interferon gamma polypeptide variants of the invention are obtained by performing selected modifications in the C-terminal part of the molecule. The full-length interferon gamma polypeptide variants of the invention are useful in ... 05/04/06 - 20060093579 - Human recombinant beta-interferon with improved solubility The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu(5), Phe(8), Phe(15), Leu(47), Phe(50), Leu(106), Phe(111), Leu(116), Leu(120) and Phe(156) is exchanged with hydrophilic amino acid with a hydroxy group, specially serine, ... 05/04/06 - 20060093578 - Method and composition for treating multiple sclerosis A method of treating multiple sclerosis including administering Interferon-β and a phosphodiesterase inhibitor in combination in a therapeutically effective amount. ... 04/20/06 - 20060083715 - Interferon beta-like molecules for treatment of stroke The present invention relates to use of interferon beta-like polypeptides for treatment of stroke or transient ischemic attach in a primate, preferably in a human. More particularly, the interferon beta-like polypeptides differs from the amino acid sequence of wild-type human IFNB (SEQ ID NO:2) in that at least one glycosylation ... 04/20/06 - 20060083714 - Combination of a pde iv inhibitor and a tnf-alpha antagonist The subject invention relates to therapeutic combinations and methods for the treatment of inflammatory conditions and diseases. Particularly the present invention relates to treatments and methods for PDE IV-related conditions and for TNF-alpha-related conditions using a combination of a PDE IV inhibitor and a TNF-alpha antagonist. ... 04/13/06 - 20060078539 - Remedies for tumor in hematopoietic organs An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an anti-tumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and ... 03/16/06 - 20060057106 - Freeze-dried interferon-y composition for transpulmonary administration and inhalation system therefor The present invention provides a freeze-dried interferon-γ composition for transpulmonary administration which can maintain IFN-γ stably, and can be prepared into fine particles in a vessel at the time of use. A freeze-dried interferon-γ composition for transpulmonary administration of the present invention has the following properties (i) to (iv): (i) ... 02/16/06 - 20060034801 - Method for treating or preventing ischemia reperfusion injury or multi-organ failure This invention relates to a method for prevention or treatment of ischemia reperfusion injury or multi-organ failure in an individual by administering to said individual an effective amount of an interferon beta. ... 02/09/06 - 20060029572 - Treatment of hepatitis c in the asian population with subcutaneous interferonbeta The present invention relates to the use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race, which failed to respond to a previous treatment with interferon-alpha, is herein reported. According to a preferred embodiment of the ... 02/02/06 - 20060024271 - Treatments for viral infections using ifn cytokines and ribavirin, alone or in combination A treatment or prophylaxis for viral infection using interferon (IFN) cytokines alone or in combination with ribavirin is provided. The treatments and prophylaxis allow for lowered dosages of IFNs, reduced pro-inflammatory responses, and delays the initiation time and reduced frequency of the IFN treatment required. ... 01/26/06 - 20060018875 - Interferon compositions and methods of use thereof The present invention provides compositions, including pharmaceutical compositions, comprising IFN-α and IFN-γ. The present invention further provides methods of treating various disorders, the methods comprising administering an effective amount of a subject composition. ... 01/12/06 - 20060008447 - Stabilized interferon compositions Stabilized pharmaceutical formulations comprising IFN-β and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-β adducts in comparison with IFN-β formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-β or a variant thereof in ... 01/05/06 - 20060002892 - Llt uses thereof in immune system modulation Natural killer (NK) cells possess the inherent capacity to kill various tumor and virally infected cells and mediate the rejection of bone-marrow grafts in lethally irradiated animals. A large family of NK cell receptors belong to the C-type lectin super-family. Genes in the NK gene complex encode type II receptors ... 12/15/05 - 20050276786 - Therapeutic modulation of the tumor inflammatory response The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1 inflammatory response in the tumor tissue, whereby the tumor tissue is diminished or destroyed and the patient develops immune memory ... 12/15/05 - 20050276785 - Treatment of cardiomyopathy and of endothelial dysfunction The present invention relates to pharmaceutical compositions comprising a therapeutically effective dose of an isolated interferon (IFN) or IFN mutein for treatment of cardiomyopathy and of endothelial dysfunction, and to methods of treating cardiomyopathy and methods of treating endothelial dysfunction using such pharmaceutical compositions. Particularly, the pharmaceutical compositions of the ... 12/01/05 - 20050265969 - Therapeutic chemokine receptor antagonists The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition ... 11/24/05 - 20050260155 - Compositions and methods for treatment of ulcerative colitis The present invention relates to the identification of TCP-1 gamma as a protein whose expression is decreased in patients with ulcerative colitis and Crohn's disease. This protein interacts with hTM5, which is involved in the pathogenesis of ulcerative colitis. Compositions and methods for diagnosis and treatment, including methods for following ... 11/10/05 - 20050249703 - Polynucleotides encoding s99t interferon gamma polypeptide variants and means of expression The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide ... 10/06/05 - 20050220764 - Higher-doses of interferon-beta for treatment of multiple sclerosis The present invention relates to pharmaceutical compositions comprising a new, therapeutically effective dose of an isolated interferon-beta (IFN-β) mutein for treatment of multiple sclerosis (MS) and methods of treating MS using such pharmaceutical compositions. More particularly, the pharmaceutical compositions of the present invention comprise a new, therapeutically effective dose of ... 09/29/05 - 20050214254 - Cysteine variants of beta interferon The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in ... 09/15/05 - 20050201982 - Polynucleotides encoding interferon gamma peptide variants When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome ... 09/08/05 - 20050196380 - Method for delivering therapeutic proteins to the intradermal compartment The present invention relates to methods and devices for intradermal delivery of substances, preferably therapeutic substances by targeting the substance to the intradermal compartment of a subject's skin. Substances delivered in accordance with the methods of the invention have an improved clinical utility and therapeutic efficacy relative to other drug ... 09/01/05 - 20050191276 - Treatment of inflammatory bowel disease through induction of indoleamine 2.3-dioxygenase Methods and compositions for treating inflammatory bowel disease based upon increasing activity of indoleamine 2,3-dioxygenase in antigen presenting cells are disclosed. ... 08/25/05 - 20050186177 - Liquid interferon-beta formulations The present invention relates to liquid formulations of human interferon-β. The formulations are characterized in that they have a buffer with a pH in the weakly acidic to neutral range of between 5 and 8, preferably between over 5.5 and 8, and that they exhibit high stability of the interferon-β ... 08/18/05 - 20050180954 - Drug for treating bone disorders By the present invention, the relative action to promote bone formation by IFNβ was proved. The action to inhibit mineralization as shown by interferon γ is not observed with interferon β. Especially, usefulness of interferon 62 as a drug for treating bone disorders was shown, whose effect for prevention and ... 08/04/05 - 20050169887 - Method and pharmaceutical composition for treating inflammation A method of treating an inflammation in a subject in need thereof is disclosed. The method comprises locally or systemically administering to the subject IFN-gamma in an amount so as to achieve an IFN-gamma bulk tissue concentration at a site of inflammation of 1-8,000 units per kilogram body weight, thereby ... 08/04/05 - 20050169886 - Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds The invention provides heat stable aqueous solutions or gels comprising a biologically active protein and a stabilizing effective amount of a mixture of a polysaccharide and an amino acid based compound. The invention also discloses stabilized solutions or gels suitable for use in an implantable drug delivery device at body ... 07/28/05 - 20050163752 - Human interferon-beta formulations The invention provides a stable pharmaceutical composition containing biologically active human interferon-β (IFN-β), preferably IFN β-1b produced in a bacterial host, dissolved in an aqueous-based solution containing a glycine buffer at a pH of about 2.0 to about 4.0. The invention of also provides stable IFN-β lyophilizates prepared from biologically ... 07/14/05 - 20050152875 - Preventives for reinfection after liver transplantation Reinfection with the hepatitis C virus after liver transplantation is protected by administering IFN-β before liver transplantation, and thus IFN-β is useful as a reinfection protecting agent. ... 06/30/05 - 20050142110 - Hsa-free formulations of interferon-beta Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-β) and methods useful in their preparation are provided. The compositions comprise the IFN-β solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-β ... ### FreshPatents.com Support |